



January 4, 2016

## Athersys to Present at Biotech Showcase(TM) 2016

CLEVELAND, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ:ATHX) announced today that Gil Van Bokkelen, Chairman and Chief Executive Officer, will present at the Biotech Showcase™ 2016 Conference to be held January 11 through January 13, 2016 in San Francisco, California.

Details of Athersys' participation are as follows:

**Event:** Biotech Showcase™ 2016 Conference  
**Date:** January 11, 2016  
**Time:** 3:30 p.m. Pacific Time  
**Location:** Room Market Street: Parc 55 Wyndham San Francisco Union Square Hotel

Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and potential strategic partners in one place during the course of one of the industry's largest annual healthcare investor conferences. The event is expected to bring together 2,100+ attendees representing the life science industry's most enterprising and pioneering biotech companies and major players in the drug development arena.

Now in its eighth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives.

Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

### About Athersys, Inc.

Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, cardiovascular and inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at [www.athersys.com](http://www.athersys.com).

### CONTACT:

Athersys, Inc.

William (B.J.) Lehmann, J.D. [wlehmann@athersys.com](mailto:wlehmann@athersys.com)

President and Chief Operating Officer [wlehmann@athersys.com](mailto:wlehmann@athersys.com)

Tel: (216) 431-9900 [wlehmann@athersys.com](mailto:wlehmann@athersys.com)

[wlehmann@athersys.com](mailto:wlehmann@athersys.com)

Primary Logo

Source: Athersys, Inc.

News Provided by Acquire Media